NCCN Publications and White Papers

NCCN Pharmacy Directors Forum White Paper


Recommendations on Operationalizing the Safe and Efficient Use of Biosimilars in the Clinical Setting

Abstract:
Biosimilar medications have the potential to reduce expenses to our overall healthcare system, and their adoption by payors and providers is starting to significantly increase. However, adopting these medications into a clinical setting is impacted by external as well as internal forces which create unique challenges. A working group within the Pharmacy Directors Forum of the National Comprehensive Cancer Network (NCCN) has reviewed and highlighted some of the potential challenges regarding adopting biosimilars into clinical practice. The work group has summarized several recommendations for the safe and efficient use of biosimilar medications in the clinical setting. 

 

NCCN Best Practices Committee publications


Psychology Staffing at Cancer Centers: Data From National Comprehensive Cancer Network Member Institutions
(JCO Oncology Practice, November 2020)

Abstract: 
The field of psycho-oncology is relatively undeveloped, with little information existing regarding the use of psychologists at cancer centers. Comprising 30 leading cancer centers across the United States, the National Comprehensive Cancer Network (NCCN) set out to understand the trends in its Member Institutions.

 

Creative Strategies Implemented During the Coronavirus Pandemic That Will Impact the Future of Cancer Care (JNCCN, October 2020)

Abstract:
The coronavirus pandemic has significantly impacted operations at leading cancer centers across the United States. In the midst of the chaos, at least one silver lining has emerged: the development of new, creative strategies for delivering cancer care that are likely to continue post pandemic. The NCCN Best Practices Committee, which is composed of senior physician, nursing, and administrative leaders at NCCN Member Institutions, conducted a webinar series in June 2020 highlighting the most promising and effective strategies to date. Experts from NCCN Member Institutions participated in the series to share their experiences, knowledge, and thoughts about the future of cancer care.


Current Practices for Screening and Management of Financial Distress at NCCN Member Institutions
 (JNCCN, July 2020)

Abstract:
Financial distress from medical treatment is an increasing concern. Healthcare organizations may have different levels of organizational commitment, existing programs, and expected outcomes of screening and management of patient financial distress.


Mitigation strategies for anti‐D alloimmunization by platelet transfusion in haematopoietic stem cell transplant patients: a survey of NCCN® centres
 (Vox Sanguinis, February 2020)

Abstract:
D‐negative patients are at risk of developing an alloantibody to D (anti‐D) if exposed to D during transfusion. The presence of anti‐D can lead to haemolytic transfusion reactions and haemolytic disease of the newborn. Anti‐D alloimmunization can also complicate allogeneic haematopoietic stem cell transplantation (HSCT) with haemolysis and increased transfusion requirements. The goal of this study was to determine whether cancer centres have transfusion practices intended to prevent anti‐D alloimmunization with special attention in patients considered for HSCT.